Invivo Capital, member of CataloniaBio & HealthTech, is one of the investors in the €65 million Series A financing announced by Corteria Pharmaceuticals, oversubscribed and co-leadership by US investment firm OrbiMed.
The financing will be used to bring Corteria Pharmaceuticals cardiovascular pipeline to the clinical stage.
Corteria Pharmaceuticals is a biopharmaceutical company specialised in the development of transformative therapies for unaddressed subpopulations of heart failure.
Heart failure is a serious disease with a prevalence of more than 60 million patients worldwide and growing. Corteria's innovative approach involves the selection of therapeutic targets implicated in acute and aggravated forms of human heart failure, as well as a stratification strategy to identify specific subgroups that are most likely to benefit from treatments. These forms of heart failure are widespread, life-threatening and not directly addressed by current standards of care.
Comments